A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
Completed
GlaxoSmithKline
Phase 2
2008-02-01
This study is an 8 day, randomised, double blind, 2-way crossover trial of repeat doses of
intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects
with seasonal allergic rhinitis (SAR). Laboratory safety assessments, 12-lead
electrocardiograph (ECG), vital signs and adverse event enquiries will be made throughout the
study. Nasal examination, symptom scores, and allergen challenge assessments will also be
performed at various time points throughout the study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
